Completed PHASE3 INTERVENTIONAL 1-arm NCT00773968

A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia (ORION)

A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once Monthly Administration of Subcutaneous C.E.R.A. for the Maintenance of Haemoglobin Levels in Pre-Dialysis Patients With Chronic Renal Anaemia

Sponsor: Hoffmann-La Roche

Conditions Anemia

Interventions Methoxy Polyethylene Glycol-Epoetin Beta

Updated 6 times since 2017 Last updated: Mar 4, 2016 Started: Sep 30, 2008 Primary completion: Mar 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Anemia, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 6 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albano Laziale, Italy , Alessandria, Italy , Ancona, Italy , Barletta, Italy , Bologna, Italy , Campobasso, Italy , Caserta, Italy , Catania, Italy , Chivasso, Italy , Cinisello Balsamo, Italy and 24 more locations